Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
Adherence to treatment
Hepatitis C virus
Hepatitis eradication
Opioid substitution therapy, OST
People who inject drugs, PWID
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
08
12
2020
accepted:
29
03
2021
pubmed:
26
5
2021
medline:
23
7
2021
entrez:
25
5
2021
Statut:
ppublish
Résumé
To assess the adherence to treatment, sustained virologic response (SVR) rate, and reinfection rate in hepatitis C patients with and without intravenous drug use. This retrospective study included hepatitis C patients, evaluated and treated in our hepatology outpatient clinic between January 2014 and October 2019. The following information was extracted from the patient's file: the presence of positive viral load for hepatitis C virus (HCV), active and recent (in the last 6 months) use of i.v. drugs, HCV genotype, treatment regimen, SVR, HCV reinfection rate, coinfection with human immunodeficiency virus (HIV) and ongoing opioid substitution therapy (OST). We included 431 hepatitis C patients, 234 people who inject drugs (PWID) and 197 non-PWID. Most patients were treated with direct-acting antivirals (DAA) only. The rate of documented SVR by treated patients was significantly higher in the non-PWID cohort (91.5% vs. 61.5%, p < 0.0001), while noncompliance (did not show up to start treatment) rate or refusal of treatment was significantly higher in the PWID cohort (19.4% vs. 8.9%, p = 0.004). In the PWID cohort, younger age and recent (in the last 6 months) or ongoing i.v. drug use was associated with noncompliance: 31.1 ± 8.4 years vs. 35.8 ± 10.6 years (p = 0.02) and 33.3% vs. 12.8% (p = 0.0008), respectively. Ongoing OST was associated with better compliance: 61.1% vs. 46.1% (p = 0.04). To achieve elimination of hepatitis C better treatment strategies are needed, especially in PWIDs.
Identifiants
pubmed: 34032930
doi: 10.1007/s00508-021-01868-1
pii: 10.1007/s00508-021-01868-1
doi:
Substances chimiques
Antiviral Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
641-646Informations de copyright
© 2021. Springer-Verlag GmbH Austria, part of Springer Nature.
Références
WHO. Global surveillance and control of Hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Liver. 1999;6:34–5.
https://www.who.int/news-room/fact-sheets/detail/hepatitis-c . Accessed: 12. October 2020.
Kandeel A, Genedy M, El-Refai S, et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45–53.
doi: 10.1111/liv.13186
Gheorghe L, Csiki IE, Iacob S, et al. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006–2008. J Gastrointestin Liver Dis. 2010;19:373–9.
pubmed: 21188327
https://cdafound.org/dashboard/polaris/maps_prev.html . Accessed 28 Mar 2020.
The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.
doi: 10.1016/S2468-1253(16)30181-9
Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–10.
doi: 10.1056/NEJM198911303212204
Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 1995;23(Suppl 2):8–12.
pubmed: 8720287
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.
doi: 10.1016/S0140-6736(01)06102-5
Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012;56:2039–50.
doi: 10.1002/hep.25892
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–893.
doi: 10.1056/NEJMoa1316366
Afdhal N, Zeuzem S, Kwo P, et al. ION‑1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.
doi: 10.1056/NEJMoa1402454
Toyoda H, Atsukawa M, Watanabe T, et al. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2019; https://doi.org/10.1111/jgh.14874 .
doi: 10.1111/jgh.14874
pubmed: 31609495
Buggisch P, Wursthorn K, Stoehr A, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS ONE. 2019;14:e214795.
doi: 10.1371/journal.pone.0214795
World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021. Geneva: World Health Organization; 2016.
Heffernan A, Cooke GS, Nayagam S, et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319–29.
doi: 10.1016/S0140-6736(18)32277-3
Pedrana A, Howell J, Schröder S, et al. Eliminating viral hepatitis: the investment case. Doha: World Innovation Summit for Health; 2018.
https://cdafound.org/dashboard/polaris/maps.html#pablo . Accessed 28 Mar 2020.
Burnet Institute. The Prime study: treating hepatitis C in primary healthcare setting. 2018. www.burnet.edu.au . Accessed: 12. October 2020.
Litwin AH, Agyemang L, Akiyama M, et al. The PREVAIL Study: Intensive models of HCV care for people who inject drugs. J Hepatol. 2017;66(Supplement):72.
doi: 10.1016/S0168-8278(17)30406-3
Schmidbauer C, Schuetz A, Schwanke C, et al. Interim results of an ongoing project to eliminate chronic hepatitis C in people who inject drugs with ongoing intravenous drug use and a high risk of non-adherence to direct-acting antivirals in Vienna. J Hepatol. 2019;70:e239.
doi: 10.1016/S0618-8278(19)30452-9
Alimohammadi A, Holeksa J, Thiam A, et al. Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting. Open Forum Infect Dis. 2018;5:ofy120.
doi: 10.1093/ofid/ofy120
Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.01.025 .
doi: 10.1016/j.jhep.2020.01.025
pubmed: 33220331
pmcid: 7410797
Rossi C, Butt ZA, Wong S, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69:1007–14.
doi: 10.1016/j.jhep.2018.07.025